South Korea’s Kolon Life Science Inc. has granted Mitsubishi Tanabe Pharma Corp. exclusive rights to develop and commercialize in Japan Invossa, the world's first cell-mediated gene therapy for osteoarthritis (OA), in a deal worth KRW500bn ($437.8m) plus sales royalties.
Kolon/Mitsubishi Gene Therapy Pact Paves Way For More Global Deals?
In a rare large gene therapy deal, South Korea’s Kolon is making inroads into the Japanese market through Invossa, its genetically modified allogeneic cell therapy for osteoarthritis. The agreement with Mitsubishi Tanabe could pave the way for more global licensing agreements in a growing segment.
More from Deals
• By
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
• By
The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.